KRAS G12C抑制剂IBI351单药治疗晚期非小细胞肺癌癌症患者的疗效和安全性：2期关键研究结果

文章预览

SCI 26 August 2024 Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study （Journal of thoracic oncology; if = 21） Zhou Q, Meng X, Sun L, Huang D, Yang N, Yu Y, Zhao M, Zhuang W, Guo R, Hu Y, Pan Y, Shan J, Sun M, Yuan Y, Fan Y, Huang J, Liu L, Chu Q, Wang X, Xu C, Lin J, Huang J, Huang M, Sun J, Zhang S, Zhou H, Wu YL. Correspondence: syylwu@live.cn Introduction 引言 KRAS G12C mutation is a well-recognized and increasingly promising therapeutic target with significant unmet clinical needs in NSCLC patients. IBI351 is a potent covalent and irreversible inhibitor of KRAS G12C. Here, we present the efficacy and safety of IBI351 from an open-label, single-arm, phase 2 pivotal study. KRAS G12C突变是一个公认的、越来越有前景的治疗靶点，但在非小细胞肺癌患者中，临床需求尚未得到满足。IBI351是强效的KRAS G12C共价不可逆抑制剂。在这里 ………………………………